×
About 81,010 results

ALLMedicine™ Ovarian Cancer Center

Research & Reviews  37,665 results

Downregulation of RIPK4 Expression Inhibits Epithelial-Mesenchymal Transition in Ovaria...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019379
Journal of Immunology Research; Yi H, Su YZ et. al.

Apr 15th, 2021 - RIPK4 has been implicated in multiple cancer types, but its role in ovarian cancer (OC) has not been clearly elucidated. Our data from Gene Expression Profiling Interactive Analysis, RT-PCR, and immunohistochemical analysis showed that RIPK4 was e...

The attributive value of comprehensive surgical staging in clinically early-stage epith...
https://doi.org/10.1016/j.ygyno.2021.04.007
Gynecologic Oncology; van de Vorst REWM, Hoogendam JP et. al.

Apr 14th, 2021 - Tumor positivity and upstaging rates from various surgical staging steps performed in clinically early-stage epithelial ovarian carcinoma (EOC) vary widely in literature. To quantify tumor positivity and upstaging rates for all staging surgery ste...

Retracted Daidzein exerts anticancer activity towards SKOV3 human ovarian cancer cells ...
https://doi.org/10.3892/ijmm.2021.4929
International Journal of Molecular Medicine; Hua F, Li CH et. al.

Apr 13th, 2021 - Following the publication of the above paper, a concerned reader drew to the Editor's attention that several figures contained data that bore striking similarities to data published in other papers; notably, the western blot data shown in Fig. 6 a...

Tryptophan 2, 3‑dioxygenase promotes proliferation, migration and invasion of ovarian c...
https://doi.org/10.3892/mmr.2021.12084
Molecular Medicine Reports; Zhao Y, Tao F et. al.

Apr 13th, 2021 - Tryptophan 2,3‑dioxygenase (TDO2) is a key rate‑limiting enzyme in the kynurenine pathway and promotes tumor growth and escape from immune surveillance in different types of cancer. The present study aimed to investigate whether TDO2 serves a role...

Fusion imaging in the preoperative assessment of the extension of disease in patients w...
https://doi.org/10.1002/uog.23650
Ultrasound in Obstetrics & Gynecology : the Official Jour... Moro F, Bertoldo V et. al.

Apr 13th, 2021 - Fusion imaging is an emerging technique that can fuse real time ultrasound examination with other imaging modalities such as computed tomography (CT), magnetic resonance, and positron emission tomography. The primary aim of the study was to evalua...

see more →

Guidelines  229 results

ESMO recommendations on predictive biomarker testing for homologous recombination defic...
https://doi.org/10.1016/j.annonc.2020.08.2102
Annals of Oncology : Official Journal of the European Soc... Miller RE, Leary A et. al.

Oct 2nd, 2020 - Homologous recombination repair deficiency (HRD) is a frequent feature of high-grade serous ovarian, fallopian tube and peritoneal carcinoma (HGSC) and is associated with sensitivity to PARP inhibitor (PARPi) therapy. HRD testing provides an oppor...

PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
https://doi.org/10.1200/JCO.20.01924
Journal of Clinical Oncology : Official Journal of the Am... Tew WP, Lacchetti C et. al.

Aug 13th, 2020 - To provide recommendations on the use of poly(ADP-ribose) polymerase inhibitors (PARPis) for management of epithelial ovarian, tubal, or primary peritoneal cancer (EOC). Randomized, controlled, and open-labeled trials published from 2011 through 2...

Olaparib shows 1-year survival benefit in recurrent ovarian cancer, BRCA mutations
https://www.healio.com/news/hematology-oncology/20200707/olaparib-shows-1year-survival-benefit-in-recurrent-ovarian-cancer-brca-mutations

Jul 6th, 2020 - Overall survival results from SOLO-2 showed patients with recurrent ovarian cancer and germline BRCA mutations added a year of life when treated with olaparib only, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

Patient survival greatly impacted by selection for ovarian cancer relapse surgery
https://www.healio.com/news/hematology-oncology/20200707/patient-survival-greatly-impacted-by-selection-for-ovarian-cancer-relapse-surgery

Jul 6th, 2020 - Studies presented during the ASCO2020 Virtual Scientific Program showed the benefit of validated selection tools in pursuing surgical measures for ovarian cancer relapse, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

Expert Perspective on ASCO20 Gynecologic Oncology Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200233/full/

Jul 2nd, 2020 - DESKTOP III (Abstract 6000) is a prospective, multicenter, randomized phase III study of > 400 patients with platinum-sensitive, recurrent ovarian cancer that demonstrated a clinically meaningful 7.7 month improvement in median overall survival wi...

see more →

Drugs  133 results see all →

Clinicaltrials.gov  40,473 results

Downregulation of RIPK4 Expression Inhibits Epithelial-Mesenchymal Transition in Ovaria...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019379
Journal of Immunology Research; Yi H, Su YZ et. al.

Apr 15th, 2021 - RIPK4 has been implicated in multiple cancer types, but its role in ovarian cancer (OC) has not been clearly elucidated. Our data from Gene Expression Profiling Interactive Analysis, RT-PCR, and immunohistochemical analysis showed that RIPK4 was e...

The attributive value of comprehensive surgical staging in clinically early-stage epith...
https://doi.org/10.1016/j.ygyno.2021.04.007
Gynecologic Oncology; van de Vorst REWM, Hoogendam JP et. al.

Apr 14th, 2021 - Tumor positivity and upstaging rates from various surgical staging steps performed in clinically early-stage epithelial ovarian carcinoma (EOC) vary widely in literature. To quantify tumor positivity and upstaging rates for all staging surgery ste...

Retracted Daidzein exerts anticancer activity towards SKOV3 human ovarian cancer cells ...
https://doi.org/10.3892/ijmm.2021.4929
International Journal of Molecular Medicine; Hua F, Li CH et. al.

Apr 13th, 2021 - Following the publication of the above paper, a concerned reader drew to the Editor's attention that several figures contained data that bore striking similarities to data published in other papers; notably, the western blot data shown in Fig. 6 a...

Tryptophan 2, 3‑dioxygenase promotes proliferation, migration and invasion of ovarian c...
https://doi.org/10.3892/mmr.2021.12084
Molecular Medicine Reports; Zhao Y, Tao F et. al.

Apr 13th, 2021 - Tryptophan 2,3‑dioxygenase (TDO2) is a key rate‑limiting enzyme in the kynurenine pathway and promotes tumor growth and escape from immune surveillance in different types of cancer. The present study aimed to investigate whether TDO2 serves a role...

Fusion imaging in the preoperative assessment of the extension of disease in patients w...
https://doi.org/10.1002/uog.23650
Ultrasound in Obstetrics & Gynecology : the Official Jour... Moro F, Bertoldo V et. al.

Apr 13th, 2021 - Fusion imaging is an emerging technique that can fuse real time ultrasound examination with other imaging modalities such as computed tomography (CT), magnetic resonance, and positron emission tomography. The primary aim of the study was to evalua...

see more →

News  2,443 results

BRCA1/2 Mutations Raise Risk for Endometrial Cancer, Too
https://www.medscape.com/viewarticle/948530

Apr 1st, 2021 - NEW YORK (Reuters Health) - Women with a BRCA1 or BRCA2 mutation have an increased risk for endometrial cancer (EC), and the greatest risk is for the rare subgroup of serous-like and p53-abnormal endometrial cancers in BRCA1 mutation carriers, acc...

Cytoreduction in Advanced Ovarian Cancer: 'Keep the Status Quo'
https://www.medscape.com/viewarticle/948395

Mar 29th, 2021 - Cytoreductive surgery should be considered for advanced ovarian cancer even if patients do not respond to chemotherapy, according to researchers. A retrospective, case-control study showed that optimal cytoreductive surgery is an independent predi...

NICE Recommends Ovarian Cancer combination Option on Cancer Drugs Fund
https://www.medscape.com/viewarticle/948166

Mar 25th, 2021 - NICE has published draft guidance which recommends olaparib plus bevacizumab for use within the Cancer Drugs Fund (CDF) as an option for maintenance treatment of advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or p...

Rock Musician Turned Med Student Takes Aim at Ovarian Cancer
https://www.medscape.com/viewarticle/947871

Mar 21st, 2021 - When Stephen Harris first met Guns N' Roses, they were unknown and penniless, backing up The Cult on tour. "I used to steal alcohol from our dressing room for them and get them extra guest passes so they could sell them for money," he says. "Once ...

Risk-Reducing Salpingo-Oophorectomy Could Curb Breast Cancer
https://www.medscape.com/viewarticle/947109

Mar 10th, 2021 - NEW YORK (Reuters Health) - In women with pathogenic variants in BRCA1 and BRCA2, risk-reducing salpingo-oophorectomy (RRSO) to help avoid ovarian cancer also appears to reduce breast-cancer risk, particularly within five years of surgery, accordi...

see more →

Patient Education  67 results see all →